News

Latest news

Hide mandatory notifications of trade

Commencement of subscription period for subsequent offering

19.02.2010 - Reference is made to stock exchange notice 18 February 2010 regarding completion of private placement in Nutri Pharma ASA ("NUT" or the "Company") of 50 million shares (the "Private Placement") as well as previous stock exchange notices

Reference is made to stock exchange notice 18
February 2010 regarding completion of private
placement in Nutri Pharma ASA ("NUT" or the
"Company") of 50 million shares (the "Private
Placement") as well as previous stock exchange
notices. A resolution to complete a subsequent
offering (the "Subsequent Offering") was made by the
Board of the Company on 18 February 2010, pursuant to
an authorization by the Company's general meeting on
12 February 2010. The preemptive right of all
shareholders was waived. The purpose of the
Subsequent Offering is to enable shareholders who did
not participate in the Private Placement to subscribe
for shares at the same price as in the Private
Placement.

A Prospectus for the Subsequent Offering was approved
by Oslo Børs and made public on 18 February 2010.
Reference is made to the Prospectus for full details
on the Subsequent Offering. The Prospectus will be
sent to all shareholders of the Company per 29
January 2010 as evidenced in the VPS register on 4
February 2010, and will also be available
electronically at the Company's website
www.nutripharma.com and the website of the Sole
Manager Pareto Securities AS (www.pareto.no) and the
website of Orion Securities AS (www.securities.no). 
Restrictions apply with respect to receipt of or
access to the Prospectus and with regard to offer to
subscribe shares for shareholders and persons
resident in certain jurisdictions outside of Norway,
including the United States. 

The subscription period for the Subsequent Offering
commences today, 19 February 2010 at 09:00 (CET), and
expires on 4 March 2010 at 17:30(CET).

The subscription price in the Subsequent Offering is
NOK 2,- per share.

The Company's shareholders per 29 January 2010 as
evidenced in the VPS register on 4 February 2010,
with the exception of shareholders allocated shares
in the Private Placement announced by the Company on
18 February 2010, will have the right to subscribe
and be allocated for 0.4 shares in the Company for
each existing share in the Company per 29 January
2010 as evidenced in the VPS register on 4 February
2010. The Company will not issue tradable
subscription rights. Over-subscription and
subscription without subscription rights is
permitted. If the Subsequent Offering is not fully
subscribed, all shareholders of  Nutri Pharma per 29
January 2010, in addition to shareholders in Bionor
Immuno per 29 January 2010, are entitled to subscribe
for shares in accordance with their pro rata
shareholding (based on a pro forma combined share
capital). Partial shares will not be issued, and the
Board reserves the right to round subscriptions
downwards.

Upon completion of the subsequent offering, the share
capital of the Company will be increased with up to
10 million new shares.

The expected time table for the subsequent offering
is as follows:

19 February 2010: Commencement of subscription period
and issue of subscription rights
4 March 2010: End of subscription period
On or about 8 March 2010: Allocation, distribution of
allocation letters and announcement of the final
result of the subsequent offering
11 March 2010: Payment date
On or about 18 March 2010 but not later than 15
April: Listing and first day of trading of the new
shares on Oslo Børs.

This notice does not entail a general invitation to
subscribe for shares. The Subsequent Offering is not
being and will not be made, directly or indirectly,
in or into, or by use of mails or any means or
instrumentality (including, without limitation,
facsimile transmission, telephone and internet) of
interstate or foreign commerce of, or any facilities
of a national securities exchange of, the United
States of America, its territories and possessions,
any State of the United States of America and the
District of Columbia (collectively, the "United
States") and the Subsequent Offering will not be
capable of acceptance by any such use, means,
instrumentality or facilities or from within the
United States. In addition, persons located in the
United States will not be able to exercise rights to
subscribe for the Subsequent Offering Shares pursuant
to the Subsequent Offering. 

The Subsequent Offering Shares have not been and will
not be registered under the U.S. Securities Act of
1933, as amended (the "Securities Act"), nor under
any laws of any state of the United States. Such
securities may not be offered, sold, resold or
delivered, directly or indirectly, in or into the
United States absent registration under the
Securities Act or an exemption from registration.

Oslo, 19 February 2010

For further information, please contact:
Trond Syvertsen    , CEO 
+47 23 01 09 60 / + 47 91 72 14 5

This information is subject of disclosure requirement
according to section 5-12 of the Norwegian Securities
Trading Act.